SCHEMBL3561475

SCHEMBL3561475

NC(=O)c1cc(Oc2ccc(NC(=O)C3(C(=O)O)CC3)c(F)c2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 2/20 0.47
▸ KDR P35968 11/20 0.46
▸ MET P08581 6/20 0.46
▸ MAPK14 Q16539 4/20 0.46
▸ RIPK2 O43353 3/20 0.46
▸ ABL1 P00519 3/20 0.46
▸ FLT3 P36888 3/20 0.46
▸ RET P07949 2/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ BCR P11274 2/20 0.46
▸ EPHA2 P29317 2/20 0.46
▸ LIMK1 P53667 2/20 0.46
▸ EPHA5 P54756 2/20 0.46
▸ DDR1 Q08345 2/20 0.46
▸ MAP3K1 Q13233 2/20 0.46
▸ DDR2 Q16832 2/20 0.46
▸ MAP3K20 Q9NYL2 2/20 0.46
▸ RIPK3 Q9Y572 2/20 0.46
▸ NTRK1 P04629 2/20 0.46
▸ EPHB6 O15197 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559849 0.88 MET (0.59) KDRMETMAPK14RIPK2ABL1
SCHEMBL3558768 0.88 MET (0.56) RAF1KDRMETFLT3RET
SCHEMBL3071577 0.85 MET (0.44) RAF1KDRMETMAPK14RIPK2
SCHEMBL15458165 0.84 KDR (0.51) KDRMETMAPK14RIPK2ABL1
SCHEMBL2851866 0.79 RAF1 (0.51) RAF1KDRMAPK14RIPK2ABL1
SCHEMBL2413206 0.79 AXL (0.56) KDRMETFLT3PDGFRBKIT
SCHEMBL1137179 0.78 ABL1 (0.54) RAF1KDRMETMAPK14RIPK2
SCHEMBL2860620 0.78 RAF1 (0.50) RAF1KDRMAPK14RIPK2ABL1
SCHEMBL13635722 0.78 MET (0.53) KDRMETMAPK14RIPK2ABL1
SCHEMBL2865557 0.77 ABL1 (0.52) RAF1KDRMETMAPK14RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058302-B1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2013-04-17 — — EP disclosed
US-8288538-B2 Pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-10-16 — — US disclosed
US-7855290-B2 N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-21 — — US disclosed
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) MATSUSHIMA TOMOHIRO 2010-03-25 — — US disclosed
EP-2058302-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-05-13 — — EP disclosed
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) HGF, MET, FLT4 RAF1 221/4885KDR 8/4885MET 2/4885
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) HGF, MET, HDGF RAF1 223/4885KDR 9/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback